Description

Dolutegravir sodium, the active ingredient in TiVicay, is a second-generation integrase strand transfer inhibitor (INSTI) used in HIV research. It binds to the active site of HIV integrase, blocking the integration of viral DNA into the host genome—an essential step in viral replication.

Manufactured by Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), this formulation offers 50mg per tablet, with 30 tablets per bottle. Approved under Chinese NMPA drug license HJ20150683 and assigned national code 86979474000277, it is commonly used in academic and pharmaceutical lab studies exploring antiviral mechanisms and resistance profiling.

Note: This product is intended only for laboratory research purposes. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Dolutegravir sodium functions as an HIV-1 integrase strand transfer inhibitor (INSTI). In vitro studies have shown its ability to:

• Block integration of viral DNA into host cells

• Maintain efficacy against strains resistant to earlier INSTIs

• Aid in long-term suppression modeling

• Investigate resistance mutations

• Explore antiretroviral synergy with other agents

Its high barrier to resistance makes it a key compound in modern antiviral pharmacology research.

Side Effects (For Reference Only in Models)

In preclinical and simulated research models, Dolutegravir may exhibit the following effects:

• Altered liver enzyme activity

• Increased serum creatinine

• Gastrointestinal changes

• Sleep disturbances or neuropsychiatric effects in animal models

These are observed under experimental conditions and do not imply clinical relevance.

Disclaimer

TiVicay (Dolutegravir Sodium Tablets) is strictly intended for laboratory research use only. It is not for human or veterinary consumption. Use in compliance with institutional safety standards and local regulations is required.